Enzon Pharmaceuticals Valuation

Is EZ1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EZ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EZ1 (€0.06) is trading below our estimate of fair value (€1.52)

Significantly Below Fair Value: EZ1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EZ1?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for EZ1. This is calculated by dividing EZ1's market cap by their current preferred multiple.
What is EZ1's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$6.12m

EZ1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	132.3x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does EZ1's PE Ratio compare to its peers?

The above table shows the PE ratio for EZ1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	7x
ECX Epigenomics	0.3x	n/a	€787.6k
2INV 2invest	11.8x	n/a	€59.2m
NAV NAVCO Pharmaceuticals	2.3x	n/a	CA$1.4m
FYB Formycon	13.6x	30.8%	€870.5m
EZ1 Enzon Pharmaceuticals	18.6x	n/a	€6.1m

Price-To-Earnings vs Peers: EZ1 is expensive based on its Price-To-Earnings Ratio (18.6x) compared to the peer average (7x).

Price to Earnings Ratio vs Industry

How does EZ1's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: EZ1 is good value based on its Price-To-Earnings Ratio (18.6x) compared to the European Biotechs industry average (24.7x).

Price to Earnings Ratio vs Fair Ratio

What is EZ1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EZ1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	18.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EZ1's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.